Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and Rituximab in Previously Untreated CLL
NCT00858117Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Sep 2005
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, rituximab in chronic lymphocytic leukemia (CLL), sponsored by Northwestern University. Started Sep 2005; status: completed.
02
Drugs
alemtuzumabrituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00858117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00858117.